Anika Therapeutics (ANIK) Revenue (QoQ) (2010 - 2026)
Anika Therapeutics (ANIK) Revenue (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 204.72 Mn | 137.94 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.28% |
| Dec 31, 2025 | 10.06% |
| Sep 30, 2025 | -1.42% |
| Jun 30, 2025 | 7.84% |
| Mar 31, 2025 | -14.49% |
| Dec 31, 2024 | 3.53% |
| Sep 30, 2024 | -3.79% |
| Jun 30, 2024 | 5.86% |
| Mar 31, 2024 | 1,101.10% |
| Dec 31, 2023 | -106.99% |
| Sep 30, 2023 | -6.40% |
| Jun 30, 2023 | 16.82% |
| Mar 31, 2023 | 1,460.75% |
| Dec 31, 2022 | -106.92% |
| Sep 30, 2022 | 1.53% |
| Jun 30, 2022 | 8.08% |
| Mar 31, 2022 | 2.43% |
| Dec 31, 2021 | -9.40% |
| Sep 30, 2021 | 3.65% |
| Jun 30, 2021 | 11.24% |